Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2008 08:00 ET | Source: Asphelia Pharmaceuticals

Asphelia Pharmaceuticals Announces Fall 2008 Conference Schedule

SAN DIEGO, Sept. 22, 2008 (GLOBE NEWSWIRE) -- Asphelia Pharmaceuticals, a privately held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological...
September 10, 2008 08:00 ET | Source: Asphelia Pharmaceuticals

Asphelia Pharmaceuticals Forms Premier Scientific Advisory Board

SAN DIEGO, Sept. 10, 2008 (GLOBE NEWSWIRE) -- Asphelia Pharmaceuticals announced today that several pre-eminent medical practitioners and scientists in the fields of immunology, gastroenterology,...
June 10, 2008 08:00 ET | Source: Asphelia Pharmaceuticals

Asphelia to Present At 2008 BIO International Convention in San Diego

SAN DIEGO, June 10, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological...
May 02, 2008 08:00 ET | Source: Asphelia Pharmaceuticals

Asphelia to Present At Digestive Disease Week 2008 in San Diego

SAN DIEGO, May 2, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on developing novel therapeutics for the treatment of a variety of immunological...
April 07, 2008 08:00 ET | Source: Asphelia Pharmaceuticals

Asphelia Announces Initiation of An Independent TSO Trial for Multiple Sclerosis

MADISON, Wis., April 7, 2008 (PRIME NEWSWIRE) -- As announced in the March 7th issue of the Wisconsin State Journal, Dr. John Fleming, a leading neurologist at the UW Hospital, is initiating an...
September 27, 2007 07:00 ET | Source: Asphelia Pharmaceuticals

Asphelia Pharmaceuticals Appoints Francois-Xavier Frapaise As President and Chief Executive Officer

SAN DIEGO, Sept. 27, 2007 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, Inc., a Paramount BioSciences-founded company committed to the development of new treatments for patients living with...